Madame Bioscience Public (GLOCON) Fundamentals 2026 — Revenue Analysis | SniperIQ
Madame Bioscience Public (GLOCON) is a TH-listed Consumer Cyclical company in Packaging & Containers with a market capitalization of ฿2.3B, trading at ฿0.66 on the SET. This SniperIQ fundamentals page covers Madame Bioscience Public's valuation, profitability (net margin -10.5%), revenue (฿1.5B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Madame Bioscience Public's market cap?
Madame Bioscience Public (GLOCON) has a market capitalization of approximately ฿2.3B, trading at ฿0.66 on the SET. Market cap moves with the live share price.
What is Madame Bioscience Public's P/E ratio?
Madame Bioscience Public's trailing twelve-month P/E ratio is not meaningful (negative or nil earnings), with a price-to-book (P/B) of 0.7x. Valuation multiples are best compared with Consumer Cyclical sector peers rather than read in isolation.
How profitable is Madame Bioscience Public?
Madame Bioscience Public runs a net profit margin of -10.5%, a gross margin of 27.2%, and an operating margin of -3.9%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Madame Bioscience Public generate?
Madame Bioscience Public reported revenue of ฿1.5B for fiscal year 2025, with net income of ฿46M and earnings per share (EPS) of 0.0592. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Madame Bioscience Public pay a dividend?
Madame Bioscience Public does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.
Is Madame Bioscience Public financially healthy?
Madame Bioscience Public carries a debt-to-equity ratio of 0.35x and a current ratio of 1.41x, with a market beta of -0.04. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Madame Bioscience Public a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Madame Bioscience Public (GLOCON) the key facts are: market cap ฿2.3B, revenue ฿1.5B, 52-week range 0.1-0.68. Weigh valuation, profitability, growth, and balance-sheet strength against Consumer Cyclical peers and form your own view.
Track Madame Bioscience Public's full fundamentals live
Get Madame Bioscience Public's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.